News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

An Observational Follow-Up Study for Subjects who have Participated in Aldafermin NASH Study 18-0108 (ALPINE 2/3)

Study Status:

Open for enrollment

Contact Information:

(956) 362-8047

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective is to extend the period for safety observation and collection of blood samples for up to 48 weeks after the last dose of aldafermin from subjects with non-cirrhotic NASH who have participated in Study18-0108 (Phase 2b, ALPINE 2/3).

Information: 

Principal Investigator
Jose L. Almeda, MD
Co-PI
Guillermo Duran
Sponsor
NGM Biopharmaceuticals, Inc.
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram